Sanovas introduces RegENT sinus treatment system
Life science asset holding firm Sanovas has launched its new wholly-owned subsidiary SinuGeniX and RegENT sinus treatment system (STS).
RegENT STS has been developed to advance sinus surgery by offering faster access with controlled, regional anesthetization and drug delivery.
The system provides swift and agile guide-sheath navigation with direct visualization and semi-compliant smart balloon catheter that acquires physiologic feedback of the anatomy.
The feedback will help the system to gently dilate the sinuses without fracturing the bony ostia, helping to make up the sinus passageways and leave essential anatomy intact
As per the Centers of Disease Control and Prevention (CDC), around 12.1% of the adult population or 28.5 million people are suffering from chronic sinusitis in the US.
SinuGeniX chief medical officer and RegENT sinus treatment system co-inventor Dr Chris Baker said: "Peer reviewed data suggests that more than 20% of the 13 million U.S. patients that are treated with medication for chronic sinusitis fail to respond. So, there are about 2.6 million patients looking to surgery as an ultimate solution.
"Traditional Functional Endoscopic Sinus Surgery (FESS) and, alternatively current balloon dilatation methods can 'over-fracture' the bony ostia as they open the sinus.
Sanovas' and SinuGenix's founder and RegENT STS co-inventor Larry Gerrans said: "SinuGeniX's RegENT Sinus Treatment System is a first-to-market suite of integrated tools intended to facilitate office-based treatment solutions that are safe and cost-effective.”